Overview
Augustine Therapeutics is a clinical-stage biopharmaceutical company developing selective histone deacetylase 6 (HDAC6) inhibitors for neuromuscular, neurodegenerative, and cardiometabolic diseases. The company's proprietary small-molecule platform targets HDAC6 with a novel non-hydroxamate chemotype designed to avoid off-target toxicities while maintaining therapeutic efficacy. Augustine's lead candidate, AGT-100216, entered Phase I clinical trials in 2025 for Charcot-Marie-Tooth disease, with additional programs in development for conditions including amyotrophic lateral sclerosis, Alzheimer's disease, and heart failure with preserved ejection fraction. The company aims to address unmet medical needs in chronic neurological and metabolic disorders by modulating a validated but previously challenging drug target.